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Abstract
Phosphatase and tensin homolog located on chromosome 10 (PTEN) is one of the most frequently mutated tumor
suppressors in human cancer including in glioblastoma. Here, we show that PTEN exerts unconventional oncogenic
effects in glioblastoma through a novel PTEN/mutant p53/c-Myc/Bcl-XL molecular and functional axis. Using a wide
array of molecular, genetic, and functional approaches, we demonstrate that PTEN enhances a transcriptional com-
plex containing gain-of-function mutant p53, CBP, and NFY in human glioblastoma cells and tumor tissues. The
mutant p53/CBP/NFY complex transcriptionally activates the oncogenes c-Myc and Bcl-XL, leading to increased cell
proliferation, survival, invasion, and clonogenicity. Disruption of the mutant p53/c-Myc/Bcl-XL axis or mutant p53/CBP/
NFY complex reverses the transcriptional and oncogenic effects of PTEN and unmasks its tumor-suppressive func-
tion. Consistent with these data, we find that PTEN expression is associated with worse patient survival than PTEN
loss in tumors harboring mutant p53 and that a small molecule modulator of p53 exerts greater antitumor effects
in PTEN-expressing cancer cells. Altogether, our study describes a new signaling pathway that mediates context-
dependent oncogenic/tumor-suppressive role of PTEN. The data also indicate that the combined mutational status
of PTEN and p53 influences cancer prognosis and anticancer therapies that target PTEN and p53.
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Introduction
Since its discovery, the importance and variety of functions of
phosphatase and tensin homolog located on chromosome 10 (PTEN ) in
cancer has surpassed all predictions and qualified this gene as one of
the most versatile and commonly altered tumor suppressors in human
cancer [1]. PTEN is mostly known for its negative regulatory effects
on the phosphatidylinositide 3-kinase (PI3K) pathway, which are
mediated by its lipid phosphatase activity [2–4]. However, numerous
studies also describe other activities that are believed to be primarily
exerted by nuclear PTEN [5,6]. Among tumor suppressors, PTEN is
unique because subtle changes of expression can have profound effects
on tumorigenesis [1,2,7]. Most human tumors retain some expression
of PTEN, and a subset of human tumors displays levels of PTEN only
slightly below the average levels of normal tissues [1,7]. Despite the
generally accepted tumor-suppressive functions of PTEN, a few recent
reports have described data that are seemingly inconsistent with such
functions. Although PTEN loss is frequently associated with metas-
tasis, recent reports demonstrated that there was PTEN gain from pri-
mary breast carcinoma to metastasis [8]. Moreover, PTEN was shown
to promote early renal tumorigenesis through induction of hypoxia-
inducible factor 2alpha (HIF-2α) in von Hippel Lindau null renal cell
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carcinoma [9]. Remarkably, we recently found that PTEN exerted
oncogenic effects in glioblastoma cells harboring p53 mutations
(mut-p53) [10]. However, the underpinning mechanisms of the PTEN
oncogenic effects are not known.
p53 is an important tumor suppressor that maintains genetic
stability in mammals by its multiple regulatory roles on cell cycle,
apoptosis, senescence, and differentiation [11–13]. p53 is mutated
in approximately 50% of all human cancers [14]. The vast majority
of p53 mutations in cancer are point mutations that are associated
with high mutant protein expression [15]. p53 mutations in cancer
have three, not mutually exclusive, types of outcome [15,16]: 1) muta-
tions that result in abrogation of tumor suppressor function of the
affected TP53 allele; 2) mutations that exert dominant-negative effects
over co-expressed wild-type p53 (wt-p53); 3) mutants that acquire new
activities that contribute to various stages of tumor progression and to
increased resistance to anticancer treatments. The latter are referred to
as gain-of-function mutants and comprise many of the hotspot p53
mutations [16,17]. The modes of action of gain-of-function mut-p53
are not well understood but are believed to involve direct or indirect
transcriptional activation or inhibition of gene sets other than those
regulated by wt-p53 as well as interaction with p63 and p73 [18,19].
Among other gain-of-function p53 mutants were shown to transcrip-
tionally regulate CDC25C, c-Myc, Bcl-XL, vascular endothelial growth
factor A, Id2, and FAS [20–22].
Recent work demonstrated that PTEN and wt-p53 enhance each
other’s tumor-suppressive functions [23–25]. However, to our best
knowledge, nothing is known about the mechanistic interactions
between PTEN and mut-p53 in human cancer. In the present study,
we show that PTEN exerts context-dependent oncogenic effects
through a novel PTEN/mut-p53/c-Myc/Bcl-XL axis. We show that
PTEN enhances a transcriptional complex containing mut-p53,
CBP, and NFY. The mut-p53/CBP/NFY complex binds to the pro-
moter of the oncogenes c-Myc and Bcl-XL and induces their transcrip-
tion. c-Myc and Bcl-XL induction leads to increased cell proliferation,
survival, invasion, and clonogenicity. Knockdown of any component
of the novel mut-p53/c-Myc/Bcl-XL axis and complex reversed the
oncogenic effects of PTEN. Consistent with the unexpected oncogenic
effects of PTEN in mut-p53 cells, we find that PTEN expression
is associated with worse survival than PTEN loss in mut-p53 glio-
blastoma tumors. We also show that a small molecule modulator of
p53, PRIMA-1, has greater antitumor effects when PTEN is expressed
in cancer cells. Our study therefore supports the novel idea of a dual
role of PTEN in cancer and uncovers novel mechanisms of PTEN
oncogenic effects in mut-p53 cancer cells and demonstrates their
implications for prognosis and therapy.
Materials and Methods
Cells and Reagents
U373 glioblastoma cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM; 1 g/l glucose with L-glutamine) supplemented with
Hepes buffer and 10% FBS. SNB19 glioblastoma cells were grown
in DMEM/F12 (1:1, L-glutamine, 15 mM Hepes) supplemented with
10% FBS. U87 glioblastoma cells were grown in MEM supplemented
with sodium pyruvate, sodium bicarbonate, and 10% FBS. LNZ308
glioblastoma cells and 293T cells were cultured in DMEM (4.5 g/l glu-
cose, L-glutamine, and sodium pyruvate) supplemented with 10% FBS.
GBM6 primary glioblastoma cells were grown in DMEM (4.5 g/l glu-
cose, L-glutamine, and sodium pyruvate) supplemented with 2.5% FBS.
All p53 exons were sequenced for all cells as described below. U373,
SNB19, and GBM6 harbored homozygous p53 R273H gain-of-
function mutation. LNZ308 was p53-null. The PTEN status was also
determined for all cells. U373, SNB19, U87, and LNZ308 were
PTEN-null, and GBM6 was PTEN-positive. Antibodies for immuno-
blot analysis, immunoprecipitation (IP), immunodepletion (ID), and
native polyacrylamide gel electrophoresis (PAGE) were anti-CBP (Cell
Signaling Technology, Danvers, MA), anti-NFYA (Santa Cruz Bio-
technology, Santa Cruz, CA), anti-p53 (Santa Cruz Biotechnology),
anti-p53 (Imgenex, San Diego, CA), anti–acetylated CBP (Cell Signal-
ing Technology), anti–c-Myc (Cell Signaling Technology), anti–
Bcl-XL (Cell Signaling Technology), anti–caspase-3 (Cell Signaling
Technology), anti-poly (ADP-ribose) polymerase (PARP; Cell Signaling
Technology), and anti–β-actin antibody (Santa Cruz Biotechnology).
PRIMA-1 was from Calbiochem (San Diego, CA). All other reagents
were purchased from Sigma (St Louis, MO), unless otherwise specified.
Tumor Samples
Glioblastoma patients were randomly chosen and signed separate
informed consent forms for postsurgical sampling. The procedures
were reviewed and approved by the Review Board of the University
of Virginia Health System.
Gene Silencing with Lentivirus-Based shRNA
The lentiviral vector pLKO.1-ConshRNA, pLKO.1-mp53shRNA,
pLKO.1-c-MycshRNA, pLKO.1-Bcl-XLshRNA, pLKO.1-
PTENshRNA, or pLKO.1-NFYAshRNA and lentivirus packaging
plasmids were cotransfected into 293T cells with FuGene 6 (Roche
Diagnostics, Indianapolis, IN). The viruses were harvested and filtered
with low-protein binding filters (Millex-HV, 0.45-mm polyvinylidene
difluoride; Millipore Corp, Billerica, MA). The cells were infected at
multiplicity of infection (MOI) = 10 by incubation with respective
viruses. The virus-infected cells were selected by puromycin (1 μg/ml).
Adenoviruses and Infection
Adenoviruses encoding PTEN or control green fluorescent protein
(GFP) were constructed in our laboratory according to the method
described by Vogelstein and colleagues. Adenoviruses encoding the mut-
p53 (R273H) were a kind gift by Dr Sumitra Deb (Virginia Common-
wealth University, Richmond, VA). Adenoviruses encoding the R175H
mut-p53 were from Vector Biolabs (Philadelphia, PA). Cells were in-
fected with the relevant adenoviruses (MOI = 10). PTEN and mut-p53
expressions were verified by immunoblot analysis for all experiments.
Cell Proliferation Assay
Cell proliferation was assessed with an 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium (MTS)
assay and by cell counting. The CellTiter96 AQ nonradioactive cell
proliferation kit (Promega Corp, Madison, WI) was used according to
the manufacturer’s instructions. The percentages of surviving cells from
each group relative to controls were determined by reduction/increase of
MTS. Cells were also counted with a hemocytometer for 5 days after
respective treatments and growth curves were established.
Apoptosis Assay
Apoptosis was assessed by measuring cytoplasmic histone-associated
DNA fragmentation (mononucleosomes and oligonucleosomes) using
an ELISA kit (Roche Diagnostics). The photometric enzyme immuno-
assay was performed according to the manufacturer’s instructions.
Neoplasia Vol. 15, No. 8, 2013 New Mechanism of PTEN Oncogenic Effects Huang et al. 953
Cell Invasion Assays
Cells were placed in the upper chamber of a collagen IV–coated
membrane. Ten percent FBS media were placed in the lower chamber.
After incubation overnight, cells on the upper membrane surface were
mechanically removed. Cells that had migrated to the lower side of
the membrane were fixed, stained, and counted under a microscope
in three randomly chosen fields and photographs were taken.
Colony Formation Assay
Cells were seeded in triplicates in media containing 10% FBS. After
3 weeks, the cell clones were fixed and stained with a solution con-
taining 0.5% crystal violet and 25% methanol. Colony numbers
were counted by a gel documentation system (EAGLE EYETM II;
Stratagene, La Jolla, CA).
Immunoblot Analysis
Protein expression levels were determined by immunoblot analysis.
Briefly, cells were lysed, and protein concentration was determined
by the Coomassie Plus protein assay reagent (Pierce Chemical Co,
Rockford, IL). Equal amounts of cell lysates were subjected to
immunoblot analysis with specific antibodies as previously described
[10]. Selected blots were subjected to densitometry on film, and signal
intensities were quantified.
Immunoprecipitation
IP assays were performed as previously described [10]. Briefly, equal
amounts of cell or tissue lysates were incubated with primary antibody
followed by incubation with protein A agarose (Roche Diagnostics). The
immunoprecipitates were boiled in sodium dodecyl sulfate (SDS) sample
buffer, resolved by SDS-PAGE, transferred to nitrocellulose (Bio-Rad,
Hercules, CA), and probed with respective primary antibodies. After
the blots were incubated with HRP-labeled secondary antibody (Jackson
ImmunoResearch, West Grove, PA), the signals were detected using
the enhanced chemiluminescence reagents (Amersham Life Science,
Arlington Heights, IL).
Immunodepletion
Protein samples were extracted from cells or human glioblastoma
tissues. The extracts were immunodepleted with anti-p53/anti-NFYA
antibodies. Thereafter, supernatants were immunoprecipitated with
anti-NFYA/anti-p53 antibody. The immunoprecipitates were then
subjected to immunoblot analysis with anti-CBP antibody.
Detection of Protein Complex with Native PAGE Analysis
U373 cells were infected with adenovirus encoding PTEN
(Ad-PTEN) for 2 to 3 days. After collection and lysis, equal amounts
of cell lysates were prepared in sample buffer without SDS and re-
solved by a native PAGE in Tris-glycine running buffer without
SDS. After transferring the proteins from the native PAGE to nitro-
cellulose membranes, the membranes were probed with primary anti-
body followed by Western blot analysis.
Chromatin IP
Chromatin IP (ChIP) assays were performed using the modified
enzymatic express ChIP kit (Active Motif, Carlsbad, CA). Briefly,
DNA/protein complexes were cross-linked, lysed, and vortexed and
ground to help the release and break the DNA. The DNA in the
sample was then sheared at 37°C with the enzyme mix provided
by the kit. The lysates were centrifuged, and soluble chromatin was
immunoprecipitated with the indicated antibody. The protein-DNA
complexes were collected after incubating with protein A or G agarose
beads and reverse cross-linked by heating at 65°C overnight. DNA
released from the complexes was purified using the QIAQuick spin
kit (Qiagen Inc, Valencia, CA). The purified DNA samples from the
input, immunoprecipitates without antibody (mock), or immuno-
precipitates with anti-RNA polymerase II antibody (positive control) or
specific IgG (experimental) were subjected to conventional polymerase
chain reaction analyses with specific primers for the promoter regions
of c-Myc (forward primer: 5′-AGGCGCGCGTAGTTAATTCA-3′
and reverse primer: 5′-TCGCATTATAAAGGGCCGGT-3′) or Bcl-XL
(forward primer: 5′-CGATGGAGGAGGAAGCAAGC-3′ and reverse
primer: 5′-GCACCACCTACATTCAAATCC-3′). DNA extracted
from soluble chromatin was used as input control for each reaction.
Each experiment was repeated at least three times with multiple samples.
Immunohistochemistry and Immunofluorescence
PTEN protein levels in human glioblastoma tissues were determined
by immunohistochemistry. The localization of mut-p53, CBP, or
NFYA was determined by immunofluorescence. The cells were plated
on coverslips, fixed, and permeabilized. The cells were then incubated
with relevant antibodies followed by incubation with fluorescein
isothiocyanate– or Texas Red–conjugated secondary antibodies. Simi-
lar procedures were also performed with a second primary antibody
and a differently conjugated secondary antibody.
Sequencing of p53 Exons
p53 mutations were analyzed by direct DNA sequencing. DNA was
extracted from cells or frozen tumor samples. All exons of p53 were
amplified by polymerase chain reaction with frequently used and
published specific primers for each exon as recommended by the
p53 database of the International Agency for Research on Cancer
(http://www-p53.iarc.fr/index.thml). Similarly processed samples
from normal brain or normal astrocytes were used as controls. The
resulting sequences were compared to wt-p53 sequences and mutations
were identified.
Statistics
When appropriate, two group comparisons were analyzed with a
t test and P values were calculated. The log rank test was used to
analyze correlations between the combined PTEN/p53 mutational
status and patient survival. P < .05 was considered significant.
Results
PTEN Exerts Oncogenic Effects that Are Mediated by
Gain-of-Function Mut-p53
We previously observed that PTEN has oncogenic properties in
mut-p53 glioblastoma cells. To verify and expand this observation
and determine if the oncogenic effects of PTEN are mediated by
mut-p53, we tested the effects of PTEN on cell growth and survival
in the settings of expressed or inhibited mut-p53. We restored PTEN
to PTEN-null/mut-p53 glioblastoma cells U373 and SNB19 with
Ad-PTEN and inhibited gain-of-function mut-p53 (R273H) with
specific shRNAs and studied the effects of these manipulations on
cell proliferation using an MTS assay and cell counting and on apop-
tosis by measuring DNA fragmentation with an ELISA. PTEN resto-
ration increased the growth of U373 and SNB19 cells. Knockdown
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of mut-p53 inhibited cell growth, consistent with the gain-of-function
characteristics of this mutant. The induction of cell growth by PTEN
was reversed when mut-p53 was inhibited (Figures 1A and W1).
PTEN restoration also inhibited apoptosis in U373 and SNB19 cells.
Knockdown of mut-p53 increased apoptosis in the cells, consistent
with the gain-of-function characteristics of the mutant. The inhibi-
tion of apoptosis by PTEN was reversed when mut-p53 was inhib-
ited (Figure 1B). PTEN reconstitution and mut-p53 knockdown in
the cells were confirmed by immunoblot analysis (Figure 1C).
We also investigated the effects of PTEN on clonogenicity and the
involvement of mut-p53 in mediating these effects using a colony
formation assay. PTEN restoration increased the clonogenicity of
mut-p53 cells. Mut-p53 knockdown significantly suppressed the clono-
genicity of the cells. Mut-p53 knockdown not only inhibited but also
reversed the clonogenic effects of PTEN (Figure 2). One of the most
detrimental hallmarks of malignant glioblastoma is invasiveness, which
is considered a major cause of tumor recurrence and patient lethality
[26]. We tested the effects of PTEN and mut-p53 on cell invasion
using a transwell invasion assay. PTEN restoration increased and
mut-p53 knockdown inhibited the invasive ability of U373 and
SNB19 cells. The effects of PTEN on invasion were reversed after
knockdown of mut-p53 expression (Figure 1D).
Additionally, knockdown of PTEN or mut-p53 suppressed cell
growth and invasion and induced apoptosis in wt-PTEN/mut-p53
GBM6 primary glioblastoma cells (Figure 3). To exclude off-target
effects of shRNA, we performed similar experiments to all of the
above with a second shRNA for mut-p53 and obtained consistent
results (Figure W2). In addition, to determine if restored PTEN is
expressed in the cytoplasm and/or nucleus, we assessed the presence
of PTEN protein in cytoplasmic and nuclear fractions of U373
and SNB19 cells after infection with Ad-PTEN. PTEN was protein
found mainly in the cytoplasm but was also detected in the nucleus
(Figure W3).
Altogether, the above data demonstrate that PTEN exerts tumor on-
cogenic effects that are mediated by gain-of-function mut-p53. We next
investigated the mechanisms underlying this intriguing phenomenon.
Figure 1. PTEN exerts oncogenic effects that are mediated by gain-of-function mut-p53. (A) MTS assay of PTEN-null/mut-p53 U373 and
SNB19 glioblastoma cells with or without PTEN restoration with Ad-PTEN and/or with or without mut-p53 silencing with shRNA (sh-mp53).
(B) Apoptosis assay of U373 and SNB19 cells with or without Ad-PTEN and/or with or without sh-mp53. (C) Immunoblot showing the levels of
mut-p53 silencing and PTEN restoration and their effects on apoptotic regulators PARP and caspase-3 in glioblastoma cells. (D) Transwell
invasion assay of U373 and SNB19 cells with or without Ad-PTEN and/or with or without sh-mp53. Con, control; *P < .05.
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PTEN Induces the Expression of Gain-of-Function Mut-p53
Target Genes in Glioblastoma Cells
The best studied mechanism of action of gain-of-function mut-p53
is the transcriptional regulation of genes other than those regulated
by wt-p53. We therefore hypothesized that PTEN might acquire
tumor-promoting effects by enhancing the transcriptional activities of
mut-p53. To test this hypothesis, we investigated the effects of PTEN
on mut-p53 target genes c-Myc, Bcl-XL, p27, E2F1, Id2, NFκB, cdc34,
Figure 2. PTEN induces clonogenicity of glioblastoma cells through mut-p53/c-Myc/Bcl-XL. Colony formation assay of PTEN-null/mut-p53
U373 and SNB19 glioblastoma cells with or without PTEN restoration with Ad-PTEN and/or with or without mut-p53/c-Myc/Bcl-XL silencing
with shRNA (sh-mp53/sh-c-Myc/sh-Bcl-XL). (A) Colony formation assay. (B) Quantification of A.
Figure 3. PTENandmut-p53 silencing inhibitsmalignancy in primary glioblastomaGBM6 cells. (A) Immunoblot showing PTENsilencingwith
shRNA (sh-PTEN) in wt-PTEN/mut-p53 GBM6 cells. (B) Proliferation assay of GBM6 cells with or without sh-PTEN. (C) Apoptosis assay of
GBM6 cells with or without sh-PTEN. (D) Phenotypic changes of GBM6 cells with or without sh-PTEN. (E) Transwell invasion assay of GBM6
cells with or without sh-PTEN. (F) Immunoblot showing mut-p53 silencing with shRNA (sh-mp53) in wt-PTEN/mut-p53 GBM6 cells.
(G) Proliferation assay of GBM6 cells with or without sh-mp53. (H) Apoptosis assay of GBM6 cells with or without sh-mp53. (I) Phenotypic
changes of GBM6 cells with or without sh-mp53. (J) Transwell invasion assay of GBM6 cells with or without sh-mp53.
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JNK, Rab27a, and TGFIIRβ, which are also known to play a role
in GBM malignancy. We restored PTEN to U373 and SNB19 by
infection with Ad-PTEN and assessed the cells for target protein ex-
pression with immunoblot analysis. PTEN restoration did not affect
the expression of putative mut-p53 target genes Id2, NFκB, cdc34,
JNK, Rab27a, and TGFIIRβ (data not shown). However, PTEN resto-
ration did increase the expression of c-Myc by 4.2- and 1.6-fold in
SNB19 and U373, respectively. Similarly, PTEN restoration increased
the expression of Bcl-XL by 3.7- and 1.8-fold in SNB19 and U373,
respectively (Figure 4A). Conversely, PTEN knockdown with specific
shRNA reduced the expressions of c-Myc by 96% and Bcl-XL by 60%
in GBM6 cells (Figure 4B). To determine if mut-p53 mediates the
induction of c-Myc and Bcl-XL by PTEN, we tested the effects of
PTEN restoration on c-Myc and Bcl-XL with or without mut-p53
knockdown with shRNA. Mut-p53 knockdown decreased the expres-
sions of Bcl-XL and c-Myc in SNB19 cells but not in U373 cells.
PTEN restoration increased the expressions of both proteins in the
setting of expressed mut-p53 but not when mut-p53 was silenced with
shRNA (Figure 4C ). Mut-p53 knockdown did not influence p-Akt
level in U373 and SNB19 cells. PTEN reconstitution reduced p-Akt
in both cells (Figure 4C ). Mut-p53 knockdown and PTEN restora-
tion were verified by immunoblot analysis. Altogether, the above
data show that PTEN induces c-Myc and Bcl-XL in a mut-p53–
dependent manner.
To further confirm these data, we used the PTEN-null/p53-null
GBM cell line LNZ308. We restored PTEN and mut-p53 expression
to the cells by infection with Ad-PTEN and/or Ad-mut-p53 (R273H).
Immunoblot analysis confirmed the expressions of PTEN andmut-p53
in the cells. Restoration of PTEN or mut-p53 alone did not signifi-
cantly alter the expression levels of Bcl-XL and c-Myc in the cells.
However, combined PTEN and mut-p53 expressions significantly
increased the levels of c-Myc and Bcl-XL (Figure 4D). To determine
if the effects of PTEN on c-Myc and Bcl-XL are specifically mediated
by the R273H mutant, we also conducted similar experiments to the
above using the R175H mutant. Neither PTEN nor R175H mut-p53
affected c-Myc or BcL-XL expressions, suggesting that specific p53
mutations are required for PTEN to exert its tumor-promoting effects
(Figure W4).
Altogether, the data presented in this section demonstrate that
PTEN enhances the induction by gain-of-function mut-p53 of the
levels of the oncogenes c-Myc and Bcl-XL in glioblastoma.
c-Myc Partially Mediates the Oncogenic Effects of PTEN
in Mut-p53 Glioblastoma Cells
We investigated the possible involvement of mut-p53–induced
c-Myc in mediating the oncogenic effects of PTEN. We studied the
effects of PTEN on cell proliferation, apoptosis, and invasion of U373
and SNB19 cells in the settings of inhibited or expressed c-Myc. PTEN
was restored to the cells by Ad-PTEN infection and c-Myc expression
was silenced with specific shRNA, before evaluation of cell prolifera-
tion, apoptosis, and clonogenicity. PTEN restoration enhanced the
growth of U373 and SNB19 cells. c-Myc knockdown inhibited growth
of the cells. Particularly, c-Myc knockdown not only inhibited but also
reversed PTEN-induced cell growth (Figure 5A). PTEN restoration
suppressed apoptosis in U373 and SNB19 cells. c-Myc knockdown
increased apoptosis, reduced PTEN-induced suppression of apoptosis
in U373 cells, and reversed the effects of PTEN on SNB19 cells
(Figure 5B). We also assessed the effects of PTEN restoration and
Figure 4. PTEN induces the expressions of mut-p53 target genes c-Myc and Bcl-XL in cancer cells. (A) Immunoblots showing the expres-
sions of Bcl-XL and c-Myc in U373 and SNB19 cells with or without PTEN restoration with Ad-PTEN. (B) Immunoblots showing the expres-
sions of c-Myc and Bcl-XL in wt-PTEN/mut-p53 GBM6 primary glioblastoma cells with or without Ad-PTEN. (C) Immunoblots showing the
expressions of Bcl-XL and c-Myc in U373 and SNB19 cells with or without Ad-PTEN and/or with or without mut-p53 silencing with shRNA
(sh-mp53). (D) Immunoblots showing the expressions of Bcl-XL and c-Myc in PTEN-null/p53-null LNZ308 cells with or without Ad-PTEN
and/or with or without mut-p53 restoration with adenovirus-encoding mut-p53 (Ad-mp53).
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c-Myc inhibition on apoptosis by immunoblot analysis for PARP and
caspase-3. PTEN restoration increased the expression of c-Myc and
inhibited PARP cleavage in U373 and SNB19 cells. c-Myc knock-
down induced PARP cleavage and caspase-3 activation and counter-
acted PTEN-induced inhibition of PARP cleavage in the cells. PTEN
restoration further enhanced c-Myc knockdown-induced PARP cleavage
and caspase-3 activation in SNB19 cells but not in U373 cells
(Figure 5C ). PTEN reconstitution increased the clonogenic ability
of U373 and SNB19 cells. c-Myc knockdown suppressed the clono-
genicity of the cells. c-Myc knockdown reversed the effects of PTEN
on clonogenicity (Figure 2). PTEN restoration increased transwell
invasion of the above mut-p53 cells. c-Myc knockdown inhibited
the transwell invasion of the cells. c-Myc knockdown reversed the
invasion-promoting effects of PTEN in the cells (Figure 5D). PTEN
restoration and c-Myc silencing were verified by immunoblot analy-
sis for all experiments. In addition, similar results to the above were
obtained with a second shRNA for c-Myc to exclude off-target effects
of the shRNAs (Figure W2).
Altogether, the above data demonstrate that c-Myc partially mediates
the oncogenic effects of PTEN in mut-p53 cells.
Bcl-XL Partially Mediates the Oncogenic Function of PTEN
in Mut-p53 Glioblastoma Cells
We also investigated the potential role of mut-p53–induced Bcl-XL
in mediating the oncogenic effects of PTEN in glioblastoma cells. We
studied the effects of PTEN on cell proliferation, apoptosis, invasion,
and colony formation of U373 and SNB19 cells in the setting of
inhibited or expressed Bcl-XL. PTEN was reconstituted to the cells
by Ad-PTEN infection and Bcl-XL expression was silenced with spe-
cific shRNA. Bcl-XL knockdown not only inhibited but also reversed
PTEN-induced cell proliferation (Figure 6A). PTEN restoration inhib-
ited and Bcl-XL knockdown increased apoptosis in the mut-p53 cells.
Bcl-XL knockdown not only inhibited but also reversed PTEN-
induced inhibition of apoptosis (Figure 6B). We also evaluated the
effects of PTEN reconstitution and Bcl-XL inhibition on apoptosis
by immunoblot analysis for PARP and caspase-3. Restoration of
Figure 5. c-Myc partially mediates the oncogenic effects of PTEN in mut-p53 glioblastoma cells. (A) Proliferation assay of U373 and SNB19
cells with or without PTEN restoration with Ad-PTEN and/or with or without c-Myc silencing with shRNA (sh-c-Myc). (B) Apoptosis assay of
U373 and SNB19 cells with or without Ad-PTEN and/or with or without sh-c-Myc. (C) Immunoblot showing the levels of c-Myc silencing
and PTEN restoration and their effects on apoptotic regulators PARP and caspase-3 in glioblastoma cells. (D) Transwell invasion assay of
U373 and SNB19 cells with or without Ad-PTEN and/or with or without sh-c-Myc. Con, control; *P < .05.
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PTEN increased expression of Bcl-XL in both U373 and SNB19 cells.
PTEN reconstitution inhibited PARP cleavage and Bcl-XL knock-
down enhanced PARP cleavage and caspase-3 activation in the cells.
PTEN restoration further increased Bcl-XL knockdown-induced
PARP cleavage and caspase-3 activation in the cells (Figure 6C ).
PTEN restoration enhanced and Bcl-XL knockdown inhibited clono-
genicity of the cells. Bcl-XL knockdown reversed the PTEN effects
on clonogenicity (Figure 2). Bcl-XL knockdown did not affect the
invasive ability of the cells. However, Bcl-XL knockdown did inhibit
PTEN-induced invasion but to a lesser extent than that observed in
c-Myc knockdown experiments (Figure 6D). PTEN restoration and
Bcl-XL silencing were verified by immunoblot analysis for all experi-
ments. In addition, similar results to above data were obtained with
another shRNA for Bcl-XL to exclude off-target effects of the shRNAs
(Figure W2).
Altogether, the above results show that Bcl-XL partially mediates
specific oncogenic effects of PTEN in mut-p53 glioblastoma cells.
There Exists a Mut-p53/CBP/NFYA Complex in Human
Glioblastoma Cells and Tumors
We next investigated the mechanism underlying the PTEN-
induced increase in c-Myc and Bcl-XL in mut-p53 glioblastoma cells.
NFY is a heterotrimeric transcription factor that is present in 30% of
eukaryotic promoters. It consists of three subunits, NFYA, -B, and
-C [27]. NFY can interact with both wt-p53 and mut-p53. CBP
plays an important role in increasing histone acetylation and tran-
scription of target genes [18,21]. To determine if a mut-p53/CBP/
NFY complex exists in mut-p53 glioblastoma cells, we performed IP
experiments with the protein extracts from U373 and SNB19 cells.
The results identified complexes containing at least two of the three
proteins (Figure 7A). Immunostaining experiments further confirmed
these results (Figure W5).
These above data suggest two possibilities for associations of the
three proteins: 1) all three proteins interact to form one single protein
complex, and 2) three possible heterodimers consisting of mut-p53/
Figure 6. Bcl-XL partially mediates the oncogenic effects of PTEN in mut-p53 glioblastoma cells. (A) Proliferation assay of U373 and SNB19
cells with or without PTEN restoration with Ad-PTEN and/or with or without Bcl-XL silencing with shRNA (sh-Bcl-XL). (B) Apoptosis assay
of U373 and SNB19 cells with or without Ad-PTEN and/or with or without sh-Bcl-XL. (C) Immunoblot showing the levels of Bcl-XL silencing
and PTEN restoration and their effects on apoptotic regulators PARP and caspase-3 in glioblastoma cells. (D) Transwell invasion assay of
U373 and SNB19 cells with or without Ad-PTEN and/or with or without sh-Bcl-XL. Con, control; *P < .05.
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CBP, NFYA/CBP, and mut-p53/NFYA separately coexist in mut-p53
glioblastoma cells. To distinguish between these possibilities, total cell
lysates (supernatants) from U373 and SNB19 cells were immuno-
depleted with an anti-p53 antibody and immunoprecipitated with an
anti-NFYA antibody followed by immunoblot analysis with an anti-
CBP antibody. The interaction between NFYA and CBP still existed,
suggesting that the existence of mut-p53/CBP/NFYA complex could
not be confirmed. However, when the protein extracts were immuno-
depleted with anti-NFYA antibody followed by IP with an anti-p53
antibody and immunoblotted for CBP, the interaction between mut-
p53 and CBP completely disappeared, suggesting that the mut-p53/
CBP/NFYA complex exists in mut-p53 glioblastoma cells. Together,
the above data indicate the existence of a mut-p53/CBP/NFYA com-
plex but do not exclude the existence of free NFYA and/or CBP/NFYA
heterodimers outside the protein complex (Figure 7B).
To determine if the mut-p53/CBP/NFYA complex also exists in
human tumor tissues, we extracted protein from three human glio-
blastoma tumor specimens. Immunoblot analysis showed the ex-
pression of CBP, mut-p53, and NFYA in all three samples. All three
samples were determined to harbor mut-p53 based on the high ex-
pression of p53 confirmed by immunoblot analysis (Figure 6C ) and
immunohistochemistry (not shown), as mut-p53 is overexpressed in
tumor cells [15], due to mut-p53 inability to effectively activate
MDM2 [28]. IP experiments confirmed the co-existence of mut-p53,
NFYA, and CBP in human glioblastoma tissues (Figure 7C ). ID
experiments in mut-p53 glioblastoma tissues showed similar results
to those obtained from glioblastoma cells, demonstrating that the
mut-p53/CBP/NFYA complex also exists in glioblastoma tissues
(Figure 7D).
To further explore the relationship between the different proteins
in the mut-p53/CBP/NFYA complex, we disrupted the complex by
knockdown of either mut-p53 or NFYA in U373 and SNB19 cells
before PTEN restoration. The results revealed that mut-p53 knock-
down slightly reduced the interaction between NFYA and CBP,
whereas NFYA knockdown strongly reduced the interaction between
mut-p53 and CBP (Figure 7, E and F ). These results further support
the existence of the complex in mut-p53 cells.
Altogether, the above data show that mut-p53/CBP/NFYA exists
as a multiprotein complex in glioblastoma cells and tissues.
PTEN Regulates Mut-p53/CBP/NFYA Binding to the Promoters
of the Mut-p53 Target Genes c-Myc and Bcl-XL
Having demonstrated the existence of a mut-p53/CBP/NFYA com-
plex in human glioblastoma cells and tissues, we next investigated the
Figure 7. There exists a mut-p53/CBP/NFYA complex in glioblastoma cells. (A) IP experiments showing the interaction between two of
the three proteins, mut-p53, CBP, and NFYA, in U373 and SNB19 cells. C, control samples immunoprecipitated with control IgG; E, experi-
mental samples immunoprecipitated with relevant antibody; WB, immunoblot. (B) ID experiments to define the relationship between the
three proteins mut-p53, CBP, and NFYA in U373 and SNB19 cells. HC, heavy chain; PC, positive control. (C and D) IP and ID experiments
showing the relationship between the three proteins mut-p53, CBP, and NFYA in human glioblastoma (GBM) tissue samples. C, control
samples immunoprecipitated with control IgG; 3, 4, 6 are distinct GBM samples. (E) Immunoblots (WB) showing the expressions of
mut-p53 or NFYA in glioblastoma cells with or without mut-p53 and NFYA silencing with specific shRNA, sh-mp53, or sh-NFYA. (F) IP
experiments showing the changes in the interaction between mut-p53/NFYA and CBP with or without NFYA/mut-p53 silencing with
sh-NFYA or sh-mp53. C1, C2, control samples immunoprecipitated with control IgG.
960 New Mechanism of PTEN Oncogenic Effects Huang et al. Neoplasia Vol. 15, No. 8, 2013
effects of PTEN on this complex as well as the effects of the com-
plex on the promoters of the mut-p53 target genes c-Myc and Bcl-XL.
Immunofluorescence assays confirmed the interaction between PTEN
and mut-p53, which is consistent with our previous report [10]. In-
terestingly, we found a previously unknown association of PTEN
and CBP in SNB19 cells (Figure 8A). We then performed IP experi-
ments to determine if PTEN restoration affects the interaction between
mut-p53/NFYA andCBP. IP experiments showed that PTEN increased
the associations between mut-p53/NFYA and CBP in mut-p53 glio-
blastoma cells (Figure 8B). To further ascertain that PTEN affects the
association of the mut-p53/CBP/NFYA protein complex, PTEN was
reconstituted to U373 cells by Ad-PTEN infection. We then performed
native PAGE that maintains the multiprotein complex intact. Western
blot analyses with mut-p53, CBP, and NFYA antibody following
native PAGE revealed a major band >300 kDa that was clearly en-
hanced in response to PTEN restoration (Figure W6). The molecular
weight of the protein complex containing mut-p53, CBP, and NFYA
is 393 kDa [53 kDa (mut-p53) + 300 kDa (CBP) + 40 kDa (NFYA)].
Consistent with the above, we also demonstrate that free mut-p53,
CBP, and NFYA decrease following PTEN restoration (Figure W6).
Altogether, these above results suggest that PTEN restoration enhances
the association of the protein complex in mut-p53 glioblastoma cells.
Alternatively, increased complex formation could be a resultant of
increased mut-p53 expression induced by PTEN.
CBP and p300 are highly conserved and functionally related tran-
scriptional co-activators that associate with transcriptional regulators
and signaling molecules, integrating multiple signal transduction
pathways with transcriptional machinery [29]. CBP also has histone
acetyltransferase activity, allowing it to acetylate histones and other
proteins [30]. Acetylation of CBP has been demonstrated to enhance
its histone acetyltransferase activity and affect a wide variety of signal-
ing events [31]. Therefore, we chose acetylated CBP instead of CBP
itself as target to perform ChIP experiments. ChIP experiments showed
that PTEN restoration increased the binding of mut-p53, acetyl-CBP,
and NFYA to the promoter region of Bcl-XL and c-Myc (Figure 8, C
and D). PTEN knockdown suppressed the binding of mut-p53,
acetyl-CBP, and NFYA to the promoter region of both genes (Figure 8,
E–G). Additionally, knockdown of NFYA and mut-p53 to disrupt the
protein complex decreased the binding of acetyl-CBP and mut-p53/
NFYA to the promoter region of both c-Myc and Bcl-XL. Both
mut-p53 and NFYA knockdown reversed the PTEN tumor-promoting
function in mut-p53 glioblastoma cells (Figures 1 and W6). These
Figure 8. PTEN regulates mut-p53/CBP/NFYA binding to mut-p53 target genes c-Myc and Bcl-XL promoters. (A) Immunofluorescence
assays showing the interaction between PTEN and mut-p53/CBP in mut-p53 glioblastoma cells. (B) IP experiments showing the inter-
action between mut-p53/NFYA and CBP in mut-p53 glioblastoma cells in response to PTEN restoration with Ad-PTEN. C, control samples
immunoprecipitated with control IgG. (C and D) ChIP experiments showing the binding of mut-p53, acetyl-CBP, and NFYA to the promoter
regions of Bcl-XL and c-Myc with or without Ad-PTEN. PC, positive control; Ab, antibody. (E) Immunoblot showing PTEN expression in
wt-PTEN/mut-p53 GBM6 cells with or without silencing with specific shRNA (sh-PTEN). (F and G) ChIP experiments showing the binding
status of mut-p53, acetyl-CBP, and NFYA to the promoter regions of Bcl-XL and c-Myc in GBM6 cells with or without sh-PTEN.
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results suggest that PTEN regulates mut-p53/CBP/NFYA complex
binding and activation of mut-p53 target gene promoters.
Analysis of the Correlations between PTEN/p53 Mutational
Status and Glioblastoma Patient Survival
The above findings show that PTEN exerts oncogenic effects
through a novel PTEN/mut-p53/c-Myc/Bcl-XL axis in glioblastoma.
An important potential implication from these findings would be that
PTEN expression in mut-p53 tumors would negatively affect prog-
nosis and that consequently patients with PTEN-positive/mut-p53
tumors would have a worse clinical outcome than the patients with
PTEN-negative/mut-p53 tumors. To verify if this is true, we sequenced
all p53 exons in 38 human glioblastoma samples and determined
PTEN protein expression by immunohistochemistry (because PTEN
mutations usually lead to protein truncation and loss of protein ex-
pression) in the same tumor specimens. We then analyzed the rela-
tionship between the combined PTEN/p53 mutational status and
patient survival. We found that patients with PTEN-positive/mut-p53
tumors exhibited a trend toward lesser survival than the patients with
PTEN-negative/mut-p53 tumors (12.2 vs 26.5 months; P = .058).
Interestingly, patients with PTEN-negative/mut-p53 exhibited a
comparable survival magnitude to the patients with PTEN-positive/
wt-p53 tumors. Furthermore, only four tumors were PTEN-negative/
mut-p53 (Figure 9A). These clinical data are consistent with our
Figure 9. Prognostic and experimental therapeutic implications of the PTEN/mut-p53 oncogenic effects. (A) All p53 exons were sequenced
in 38 human glioblastoma samples and PTEN protein expression was determined by immunohistochemistry in the same tumor specimens.
The combined PTEN/p53 mutational status was plotted against patient survival. (B) Immunoblot showing the expressions of wt-p53 target
genes p21 and Mdm2 in mut-p53 U373 and wt-p53 U87 cells in response to PRIMA-1 treatment (left panel). Apoptosis assay of U373
and U87 cells in response to PRIMA-1 treatment (right panel). (C) Proliferation assay of U373 cells with or without PTEN restoration with
Ad-PTEN and/or with or without PRIMA-1 treatment. (D) Apoptosis assay of U373 cells with or without PTEN restoration with Ad-PTEN and/
or with or without PRIMA-1 treatment. (E) Schematic representation of the mechanisms underlying the dual oncogenic/tumor-suppressive
effects of PTEN in mut-p53 cancer cells. PTEN enhances a transcriptional complex containing mut-p53, NFY, and CBP. The mut-p53/CBP/
NFY complex binds to the promoter of the oncogenes c-Myc and Bcl-XL and induces their transcription, leading to increased cell prolifera-
tion, survival, invasion, and clonogenicity. Disruption of the mut-p53/c-Myc/Bcl-XL axis unmasks the hidden tumor-suppressive effects of
PTEN in mut-p53 cancers.
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findings in cells and further validate the oncogenic effects of PTEN in
mut-p53 glioblastoma.
Reactivation of wt-p53 Function with a Small Molecule
Modulator Reverses the Oncogenic Effects of PTEN
To determine if our findings might be exploited for future cancer
therapies, we used the small molecule modulator of p53, PRIMA-1, to
reactivate wt-p53 in mut-p53 cells before testing the effects of PTEN
restoration on apoptosis. Previous research identified PRIMA-1 as
a small molecule modulator that restores wt-p53 conformation and
DNA binding to mut-p53 (R273H and R175H) cells and induces
apoptosis preferentially in mut-p53–expressing tumor cells [32].
Mut-p53 U373 and wt-p53 U87 cells were treated with PRIMA-1,
and the expressions of the wt-p53 transcriptional targets p21 and
Mdm2 were assessed with immunoblot analysis. PRIMA-1 preferen-
tially induced p21 and Mdm2 expressions in U373 cells, indicating
that it could reactivate wt-p53 transcriptional activity in mut-p53
cells (Figure 9B). We also tested the effects of PRIMA-1 on apop-
tosis in U373 and U87 cells and found that PRIMA-1 induced
greater apoptosis in mut-p53 U373 cells (Figure 9B). We then tested
the effects of PRIMA-1 on U373 cells with or without PTEN restora-
tion. PTEN restoration enhanced and PRIMA-1 suppressed the
growth of U373 cells. PRIMA-1 reversed the effects of PTEN on the
growth of U373 cells (Figure 9C ). PTEN restoration inhibited and
PRIMA-1 induced apoptosis in U373 cells. PRIMA-1 reversed the
effects of PTEN on apoptosis in U373 cells (Figure 9D). These results
suggest that PRIMA-1 and other p53 modulators exert greater anti-
tumor effects in PTEN-expressing cancer cells and that combining
PTEN restoration with PRIMA-1 in mut-p53 tumors might have
therapeutic value.
Discussion
In this study, we show that PTEN has mut-p53–dependent oncogenic
effects. We demonstrate, for the first time, that PTEN exerts these
effects by increasing the levels of a transcriptional complex containing
mut-p53, CBP, and NFYA, which activates the oncogenes c-Myc and
Bcl-XL. We also describe an association between the combined PTEN/
p53 mutational status and patient survival and determine the effects
of PTEN expression on the experimental therapeutic restoration of
p53 function.
There is accumulating evidence that several hotspot p53 mutants
not only lose the tumor-suppressive functions of wt-p53 but also
acquire new pro-oncogenic properties leading to the concept of
“gain-of-function” mut-p53 [15,17]. Many gain-of-function pheno-
types of mut-p53 have been reported, including increased invasion,
metastasis, and genomic instability, resistance to chemotherapy,
and regulation of pro-inflammatory and anti-apoptotic pathways
[16,20], all of which give mut-p53–expressing cells a selective
growth and survival advantage. Recent research has uncovered
a multilevel and complex cooperation between wt-PTEN and
wt-p53 [23–25,33]. However, almost nothing is known about the
interactions between wt-PTEN and mut-p53. Our study provides
novel and detailed insights into these interactions and their implications
for cancer.
We show that PTEN increases the levels of gain-of-function
mut-p53 and the proliferation, survival, clonogenicity, and invasion
of glioblastoma cells in a mut-p53–dependent manner. Mut-p53
knockdown not only inhibited but also reversed the oncogenic effects
of PTEN, suggesting that knockdown of mut-p53 unmasks the hid-
den tumor-suppressive forces of PTEN, supporting our novel idea
of dual context-dependent effects of PTEN in cancer. These above
findings led us to explore the underlying mechanisms of the unconven-
tional PTEN oncogenic effects in mut-p53 glioblastoma. We found
that PTEN induces c-Myc and Bcl-XL gene expression and malignancy
through enhancement of a mut-p53–containing protein complex.
c-Myc is a key regulator of cellular outcomes in normal cells, and
its dysregulation is associated with cancer development and progres-
sion [34–36]. A key role for c-Myc is to integrate various signals so
as to orchestrate an extensive transcription program that regulates cell
proliferation, differentiation, and death [37]. We previously showed
that PTEN increases the stability and expression of mut-p53 in glio-
blastoma cells [10]. A previous study found that gain-of-function
mut-p53 increased the expression of c-Myc in cancer cells [20]. Al-
though PTEN was reported to inhibit expression of c-Myc in tumor
cells [38], we hypothesized that PTEN might increase the expression
of c-Myc in mut-p53 cells. Our data confirmed this hypothesis and
showed that PTEN can induce c-Myc in a mut-p53–dependent
manner. Functionally, c-Myc can elicit epithelial-mesenchymal transi-
tion (EMT) and metastasis in carcinomas [39]. We found that c-Myc
knockdown reversed the effects of PTEN on the growth, invasion,
and clonogenicity of the cells, suggesting that c-Myc knockdown
unveils the tumor-suppressive effects of PTEN, supporting our
hypothesis for the dual context-dependent effects of PTEN in cancer.
Bcl-XL is a mitochondrial membrane protein that promotes cell
survival by regulating the electrical and osmotic homeostasis of mito-
chondria in response to a variety of stimuli [40]. Inhibition of Bcl-XL
induces apoptosis of glioblastoma cells [41]. Gain-of-function mut-p53
was shown to upregulate the expression of Bcl-XL in cancer cells [20].
We therefore hypothesized that PTEN might induce the expression
of Bcl-XL in mut-p53 cancer cells. Indeed, we showed for the first
time that PTEN enhances the expression of Bcl-XL in a mut-p53–
dependent manner. Furthermore, Bcl-XL knockdown suppressed the
PTEN effects on cell growth, apoptosis, and colony formation, sug-
gesting that Bcl-XL mediates specific oncogenic effects of PTEN
in mut-p53 glioblastoma cells. Interestingly, Bcl-XL knockdown
reversed the effects of PTEN on the growth, clonogenicity, and sur-
vival in the cells, suggesting that Bcl-XL knockdown unmasks the
tumor-suppressive effects of PTEN.
We further investigated the molecular mechanisms of induction
of c-Myc and Bcl-XL by PTEN and mut-p53. To the best of our
knowledge, we are the first to report the existence of a protein complex
mut-p53/CBP/NFYA in glioblastoma cells and human tissues. PTEN
interacts with both mut-p53 and CBP and increases the association
of the proteins in the complex and the binding of the proteins to the
promoter region of the target genes, resulting in enhanced expressions
of c-Myc and Bcl-XL, leading to functional changes including induction
of cell growth, survival, colony formation, and invasion. Knockdown of
any component of the novel mut-p53/c-Myc/Bcl-XL axis and com-
plex reversed the oncogenic effects of PTEN and the PTEN-induced
activation of the c-Myc and Bcl-XL promoters (Figures 8 and 9E). We
therefore describe a new mechanism through which PTEN promotes
oncogenic parameters through novel PTEN/mut-p53/c-Myc/Bcl-XL
axis. However, considering the complex roles of p53 mutants, it cannot
be excluded that additional mechanisms are involved in mediating the
oncogenic effects of PTEN [20].
To determine if the PTEN oncogenic effects in the setting
of mut-p53 have potential clinical implications, we assessed the
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correlations between the PTEN/p53 mutational status and survival of
glioblastoma patients. On the basis of our findings, one would
predict that PTEN expression in tumors harboring gain-of-function
p53 mutations would negatively affect clinical outcome. In fact,
we found that patients with PTEN-positive/mut-p53 tumors had
worse clinical outcome than patients with PTEN-negative/mut-p53
tumors. The differences in survival were barely below statistical
significance, likely due to the moderate sample size of 38 tumors.
Moreover, we found only four cases of PTEN-negative/mut-p53
tumors, suggesting that the tumors lose selective advantage by losing
PTEN protein expression in the setting of gain-of-function mut-p53.
These findings are consistent with our in vitro data and in line with
previous reports that mutations in TP53 and PTEN are mutually
exclusive in other cancers [42]. These findings confirm the context-
dependent oncogenic potential of PTEN. In the setting of mut-p53,
PTEN effects are likely a balance between the well-known lipid
phosphatase-mediated tumor-suppressive effects and the oncogenic
effects mediated by mut-p53 and its gene targets. While PTEN mostly
acts as a tumor suppressor, in specific contexts its oncogenic effects
might prevail as shown in our study. Even in the latter case, the
tumor-suppressive effects of PTEN still exist because PTEN restora-
tion in U373 and SNB19 cells do reduce the level of p-Akt (Ser-473),
resulting in decreased PI3K-AKT signaling. We therefore cannot
exclude the possibility that, in specific circumstances, the tumor-
suppressive effects might dominate the role of PTEN, also in the
setting of gain-of-function mut-p53. The oncogenic effects of PTEN
in the setting of gain-of-function mut-p53 possibly also apply to human
malignancies other than glioblastoma based on preliminary data from
our laboratory (not shown). If so, our findings will be very valuable
because p53 is mutated in about half of all human tumors [14]. Our
findings also have potential prognostic and therapeutic implications.
They show that the combined PTEN/p53 mutational status is a more
accurate predictor of clinical outcome than the status of either single
gene. They imply that restoration of PTEN expression or function
should take into consideration the p53 mutational status to avoid
unwanted effects. Our data also suggest that small molecule modu-
lators of p53 are likely to have greater therapeutic effects in PTEN-
expressing cells and/or that combining PTEN restoration with p53
modulators or c-Myc/Bcl-XL inhibitors might represent new strategies
for cancer therapy.
Altogether, our study describes a novel, unconventional, and
context-dependent function of PTEN and unravels its mechanistic
basis. The findings shed new light on the complex molecular inter-
actions between PTEN, mut-p53, and its gene targets c-Myc and
Bcl-XL and have potentially important implications for prognosis and
future therapies of cancer.
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